106 related articles for article (PubMed ID: 2697403)
1. Mitoxantrone in the treatment of refractory and relapsed non-lymphoblastic acute leukaemia.
Pretnar J
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():59-60. PubMed ID: 2697403
[No Abstract] [Full Text] [Related]
2. High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B
Semin Hematol; 1991 Jul; 28(3 Suppl 4):35-8. PubMed ID: 1780750
[No Abstract] [Full Text] [Related]
3. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed and refractory acute myeloid leukemia in adults.
Lazzarino M; Morra E; Alessandrino EP; Merante S; Bernasconi P; Bonfichi M; Caldera D; Bernasconi C
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():121-3. PubMed ID: 2653487
[No Abstract] [Full Text] [Related]
5. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
6. [Combined therapy with mitoxantrone and cytosine arabinoside as a first-line treatment in ANLL: preliminary results].
Angós JA; Gutiérrez M; Moreno JA; Aguado MJ; Romero MS
Sangre (Barc); 1993 Jun; 38(3):250-1. PubMed ID: 8211557
[No Abstract] [Full Text] [Related]
7. Treatment of poor prognosis acute myeloid leukemia with aggressive and non-aggressive chemotherapy.
Stenke L; Hast R; Reizenstein P
Chemioterapia; 1987 Jun; 6(2 Suppl):723-4. PubMed ID: 3509530
[No Abstract] [Full Text] [Related]
8. [Chemotherapy of relapsed AML and ALL].
Nishikawa K
Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
[No Abstract] [Full Text] [Related]
9. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
[No Abstract] [Full Text] [Related]
11. Leukaemia due to mitoxantrone.
Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
14. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Evensen SA; Brinch L; Wisløff F
Tidsskr Nor Laegeforen; 1989 Jun; 109(19-21):2004-6. PubMed ID: 2749689
[TBL] [Abstract][Full Text] [Related]
15. Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
van der Jagt RH
Leuk Res; 2010 Jul; 34(7):856-7. PubMed ID: 20378170
[No Abstract] [Full Text] [Related]
16. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Karagiannis P; Alsdorf W; Tallarek AC; Blohm ME; Oelrich J; Waizenegger JS; Wolschke C; Hecher K; Singer D; Bokemeyer C; Fiedler W
Br J Haematol; 2021 Jan; 192(2):e60-e63. PubMed ID: 33222152
[No Abstract] [Full Text] [Related]
17. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Mariańska B; Apel D; Seferyńska I; Maj S
Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone.
Med Lett Drugs Ther; 1988 Jul; 30(769):67-8. PubMed ID: 3380059
[No Abstract] [Full Text] [Related]
19. Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Salvucci M; Zanchini R; Molinari A; Zuffa E; Poletti V; Poletti G; Zaccaria A
Haematologica; 2000 Jul; 85(7):769-70. PubMed ID: 10897135
[No Abstract] [Full Text] [Related]
20. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
